ABBV up +1.53% percent Today $ABBV High is at 64.98 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
ABBV up +1.53% percent Today $ABBV High is at 64.98 and the Low 64.03 with current volume of 1,199,311.

Recent News posted below.

Abbvie Inc. Common Stock ABBV other info.
http://investorshangout.com/AbbVie-Inc-ABBV-90091/

ABBV Abbvie Inc. Common Stock Recent Headline News

Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.23 (+0.07), GILD: 100.54 (-1.52), ABBV: 64.95 (+0.95), CELG: 104.21 (+0.16)

AbbVie to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Mon Nov 17, 6:00AM CST
AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 9:20 a.m. GMT (3:20 a.m. Central time.)
ABBV: 64.95 (+0.95)

7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 71.94 (-0.91), LLY: 67.13 (-0.20), ABBV: 64.95 (+0.95), GSK: 45.82 (+0.08), SNY: 47.30 (+0.62), NVS: 94.29 (+0.34)

AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 29.92 (-0.42), AZN: 71.94 (-0.91), ABBV: 64.95 (+0.95)

7 Aristocrat Dividend Dogs Hit 5% To 12.75% November Upsides
Fredrik Arnold - at Seeking Alpha - Fri Nov 14, 5:10PM CST

KO: 42.79 (+0.06), HCP: 44.03 (+0.45), CLX: 100.42 (+0.30), GPC: 99.83 (+0.15), TROW: 81.87 (-0.25), NUE: 53.68 (-0.23), ED: 62.28 (+0.25), SYY: 38.85 (+0.27), LEG: 40.92 (+0.14), EMR: 63.47 (-0.15), XOM: 94.46 (-0.63), PEP: 97.97 (+0.25), T: 35.82 (-0.08), CINF: 50.84 (-0.20), ADP: 84.71 (-0.04), TGT: 67.45 (-0.68), MCD: 95.69 (-0.52), ABBV: 64.95 (+0.95), CVX: 115.46 (-0.86), AFL: 58.45 (-0.86), CL: 67.66 (+0.10)

AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
PR Newswire - Fri Nov 14, 3:48PM CST
AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an aggressive form of brain cancer, which showed that of those with measurable disease and epidermal growth factor receptor (EGFR) amplification, four of 12 patients (33%) achieved an objective response, including two whom achieved complete responses. The results from the three-arm clinical trial, which evaluated ABT-414 as a monotherapy, in combination with chemotherapy, or in combination with radiation and chemotherapy, were presented at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 13-16 in Miami.
ABBV: 64.95 (+0.95)

Where Will Google Stock Be in 10 Years?
Leo Sun, The Motley Fool - Motley Fool - Fri Nov 14, 8:00AM CST
Over the past decade, Google stock has soared over 500%, fueled by the growth in search and mobile devices. Google now controls 58% of the world's Internet searches and 85% of the mobile market via Android, and it continues to disrupt Microsoft'...
AMZN: 318.34 (-9.48), FB: 74.04 (-0.84), ABBV: 64.95 (+0.95), GOOGL: 544.50 (-10.69), GOOG: 534.18 (-10.22)

The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST

JNJ: 108.23 (+0.07), GILD: 100.55 (-1.51), MRK: 59.42 (+0.35), ABBV: 64.95 (+0.95)

If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST

GILD: 100.55 (-1.51), ABBV: 64.95 (+0.95)

Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST

JNJ: 108.23 (+0.07), PFE: 29.92 (-0.42), ABBV: 64.95 (+0.95)

AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 64.95 (+0.95)

Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 29.92 (-0.42), ABBV: 64.95 (+0.95)

Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.51 (-0.46), MRK: 59.43 (+0.36), ABBV: 64.95 (+0.95)

Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 209.64 (+10.99), JNJ: 108.23 (+0.07), GILD: 100.54 (-1.52), ABBV: 64.95 (+0.95)

Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST

GILD: 100.54 (-1.52), ABBV: 64.95 (+0.95)

Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 209.64 (+10.99), ABBV: 64.95 (+0.95), SNY: 47.30 (+0.62), REGN: 401.69 (+6.49)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 111.01 (-0.33), GILD: 100.54 (-1.52), ACHN: 13.51 (-0.46), DNDN: 0.14 (+0.03), AMGN: 158.57 (+0.89), ABBV: 64.95 (+0.95), REGN: 401.69 (+6.49)

Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.11 (-0.55), ACT: 246.80 (+3.03), CBG: 32.33 (-0.07), HCP: 44.03 (+0.45), BCR: 164.38 (+0.34), PCG: 50.22 (+0.57), AMGN: 158.57 (+0.89), CB: 101.39 (+0.14), SRE: 109.53 (+0.86), PLD: 40.99 (+0.22), HSP: 58.04 (-0.24), TWX: 79.96 (+0.21), KIM: 24.73 (+0.27), CMI: 144.13 (-0.93), ALXN: 187.35 (-1.41), ESS: 200.96 (+1.89), ABBV: 64.95 (+0.95), CAT: 101.23 (-0.11), AAPL: 113.57 (-0.61)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 209.61 (+10.96), GILD: 100.54 (-1.52), ABBV: 64.95 (+0.95), BMY: 58.06 (+0.11)

Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST

ABBV: 64.95 (+0.95)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 192

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 0

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 87

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 16

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 253

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 157

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 264

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 249

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 0

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading

Top 5 Most Recently Viewed Articles

IASO Bio Achieves Major Milestone with Orphan Drug Status

Updated Category News Views 270

IASO Bio Earns Orphan Drug Designation for Breakthrough Therapy IASO Biotherapeutics, a key player in the biopharmaceutical sector, announced an exciting achievement as its groundbreaking treatment, Equecabtagene Autoleucel (Fucaso), received Orphan Drug Designation from the Ministry of Food and Drug Safety. This recognition is particularly significant for adults fighting...

Continue Reading
Transforming Experience: Honda Center's $1 Billion Revamp

Updated Category News Views 387

Transforming Experience: Honda Center's $1 Billion Revamp Honda Center Encore Is A Multi-Year Investment Led by the Samueli Family That Will Redefine the Arena Experience OC Sports & Entertainment (OCSE), connected with the operator of Honda Center, has announced a groundbreaking project known as Honda Center Encore. This ambitious venture involves a significant...

Continue Reading
PIMCO Municipal Income Fund Faces Market Pressures at New Lows

Updated Category News Views 192

PIMCO Municipal Income Fund's Recent Market Performance PIMCO Municipal Income Fund (PMF) has recently faced significant market challenges, as evidenced by its stock hitting a notable 52-week low at a price of $8.82. This decline isn't merely an isolated incident; it reflects ongoing pressures impacting the broader fixed-income sector. Investors are currently navigating...

Continue Reading
Exploring Non-Surgical Solutions for Prostate Health Issues

Updated Category News Views 174

Prostate health became a hot topic for many men over 50, especially with the rise of benign prostatic hyperplasia (BPH)—that uncomfortable enlargement that turns bathroom trips into sprints. Back then, treatment options were shaking up, and PAE was coming onto the scene like it owned the place. PAE vs. Traditional Surgery: The Fight for Relief In an era where...

Continue Reading
Applied Digital Appoints Laura Laltrello as COO for AI Growth

Updated Category News Views 245

Applied Digital Names Laura Laltrello as New COO Applied Digital Corporation (NASDAQ: APLD) is excited to announce the appointment of Laura Laltrello as its new Chief Operating Officer (COO). With an aim to strengthen the Company’s leadership in next-generation data centers and digital cloud solutions, Ms. Laltrello's role signifies a pivotal moment in the Company’s...

Continue Reading